Beech Hill Advisors Inc. raised its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,532 shares of the company’s stock after buying an additional 330 shares during the quarter. Johnson & Johnson comprises approximately 1.8% of Beech Hill Advisors Inc.’s portfolio, making the stock its 21st biggest position. Beech Hill Advisors Inc.’s holdings in Johnson & Johnson were worth $3,648,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Johnson & Johnson by 1.2% during the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after buying an additional 2,815,655 shares during the period. State Street Corp increased its holdings in shares of Johnson & Johnson by 0.6% during the third quarter. State Street Corp now owns 141,886,311 shares of the company’s stock valued at $23,178,548,000 after acquiring an additional 803,013 shares in the last quarter. Moneta Group Investment Advisors LLC increased its holdings in shares of Johnson & Johnson by 90,144.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after acquiring an additional 54,326,454 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Johnson & Johnson by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 47,958,583 shares of the company’s stock valued at $8,456,643,000 after acquiring an additional 294,671 shares in the last quarter. Finally, Morgan Stanley increased its holdings in shares of Johnson & Johnson by 12.0% during the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after acquiring an additional 4,521,062 shares in the last quarter. Hedge funds and other institutional investors own 67.57% of the company’s stock.
Johnson & Johnson Trading Up 0.7 %
Shares of NYSE:JNJ opened at $164.10 on Friday. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $181.04. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The stock has a market capitalization of $426.45 billion, a price-to-earnings ratio of 34.33, a PEG ratio of 2.79 and a beta of 0.54. The stock’s 50-day simple moving average is $160.73 and its two-hundred day simple moving average is $163.23.
Johnson & Johnson Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd were given a dividend of $1.19 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.90%. The ex-dividend date of this dividend was Monday, May 22nd. Johnson & Johnson’s payout ratio is presently 99.58%.
Insider Buying and Selling
In related news, EVP Kathryn E. Wengel sold 12,465 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.20% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
JNJ has been the subject of several analyst reports. Credit Suisse Group raised their price target on Johnson & Johnson from $168.00 to $170.00 in a report on Friday, May 5th. TheStreet downgraded Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, May 19th. Morgan Stanley lifted their price objective on Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 19th. Atlantic Securities reduced their price objective on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a report on Wednesday, April 19th. Finally, UBS Group started coverage on Johnson & Johnson in a report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $171.57.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- Is it Time To Ring The Register On Paychex?
- Micron Technology: A Reversal Is Imminent
- Can Topgolf Callaway Brands Crawl Out of the Bunker and Rally?
- McCormick Rebound Imminent: Executive Transition Complete
- 3 Reasons Boston Beer Stock Could Finally Hop Higher
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
